Artificial Organs and Medical Bionics Market

Artificial Organs and Medical Bionics Market is valued at USD 34.1 Bn in 2026 and is projected to reach USD 56.6 Bn, growing at a CAGR of 8% by 2033.

Demand All Set to Witness Rapid Growth in the Wake of a Massive Demand-Supply Gap

Human organ supply-demand imbalance, general ethical concerns while the procurement of organs, race, religion, lack of understanding of the various minority groups, difficulties in obtaining consent, contradictions to organ donation, and long waiting lists for the availability of natural organs/organ donors are demanding rapid need for availability of artificial organs and medical bionics today. There is a huge gap between organ donors and patients in need of organ transplants. According to the Nation Health Resources and Services Organization, about 20 people die on average per day owing to the lack of viable organs for transplant. Artificial organs have thus become vital as an alternative means for people in need of organ transplants. This scenario is primarily driving the growth of global artificial organs and medical bionics market.

Artificial organs and medical bionics represent a lifesaving technology relying on recent automation advances such as 3D printing, and stem cell implementation. These groundbreaking medical bionic devices are currently under development and tested globally and are expected to offer patients with organ failure the hope of prompt treatment in the future. Extensive research has been undertaken across the globe to grow a full organ using stem cells from adults. This kind of research is in a very nascent stage and lots of studies to be carried out for the organs to become available to the patients, which is expected to support the growth of artificial organs and medical bionics market.

Complexities Associated with Organ Replacement Influence Performance of Artificial Organs and Medical Bionics Market

Global artificial organs and medical bionics market registered revenue worth US$ 30.3 Bn in 2021 and is set to witness robust revenue growth between 2022 and 2027. The rising burden of diabetes, heart diseases, and kidney failure due to lifestyle disorders, coupled with growth in advancements in medical technologies observed over the recent past across the globe are known to increase the demand for organ replacement. The exorbitant cost is the main issue associated with the implementation of these high-tech organs. Moreover, certain ethical consequences exist. Biocompatibility, minimal effect on the immune system, stringent regulation, poor reimbursement coverage, risk of the device malfunction, and other related concerns are the major factors impeding the market growth.

Currently, creating substitutes for all human organs with artificial ones is a challenging task. For instance, developing endocrine organs, and liver which carry out many biological functions. Artificial devices are yet able to reproduce only a few of their vital functions with limited improvement in safety, and efficacy. The most important aspect further to be considered is the reduction of production and operation costs of present and future devices, to make them affordable for a greater number of people, especially in emerging regions of the world. This will remain a major influencing factor for artificial organs and medical bionics market.

Artificial Kidney Continues to be Sought-after Worldwide

Manufacturing of complex organs such as the heart, liver, and kidney demands a meticulous survey of the structural, chemical, and biological functions of various extracellular matrices, identifying the key molecular, structural, and mechanical cues required to maintain the organ architecture, tissue functions, and other such signals with respect to different tissues. Regardless of the mentioned drawbacks, the outlook for the artificial organs and medical bionics market is remarkably bright, as these devices have the potential to save human lives that would otherwise be lost. While implantable technology maintains its lead in the market in terms of revenue and expected to reach US$34 Bn in revenue toward the end of forecast year, kidney has been a leading segment in the market that has been foreseen to exhibit higher growth in terms of revenue. Kidney transplants will most likely retain their instrumental role for the artificial organs and medical bionics market throughout the forecast period.

Research Around Biocompatible Materials to Unlock New Doors of Opportunity in Artificial Organs and Medical Bionics Market

Metals represent a dominant market segment as they continue to be the highly suitable biomaterials for artificial organs and medical bionics. The segment is likely to reach the valuation of nearly US$17 Bn by 2027 end. A great stride in this field due to advancements in biomedical engineering is being continuously made, to increase the number of miniature artificial organs for permanent implantation in the human body. The selection of appropriate biomaterials plays a fundamental role in constructing a medical device for human use: Biocompatibility is the most important requirement of a biomaterial and is not a property of the material alone. Mechanical strength and durability are the other essential requirements. Polymers provide certain properties of chemical inertness, ease of fabrication, less cytotoxicity, flexibility, hardness, and permeability required for their application in the manufacturing of artificial organs.

Artificial Organs and Medical Bionics Market to Spread its Roots with Novel Approaches, and New Product Introduction

Artificial organ technologies have now been harnessed in therapeutic areas the future of artificial organs should not only be focused on the development of replacement organs, but also on the artificial organ technologies for therapeutic or preventative medicine. By applying aggressively these types of technologies namely organ-on-chip, certainly, the outcome of early end-stage organ failure can be prevented and the need for artificial hearts, kidneys, orthopaedic implants, and various implantable artificial organs is reduced. 3D bioprinting technology is anticipated to address the organ shortage issue in the future. According to a news article published in 2016, Pandorum Technologies, an India-based biotech startup, has developed an artificial tissue that performs the functions of the human liver. This is expected to enable affordable medical research with reduced dependence on animal and human trials, eventually leading to full-scale transplantable organs. Bioartificial organ manufacturing technologies hold the promise to greatly improve the quality of health and average lifespan of human beings soon.

Artificial Organs and Medical Bionics Market Surges Ahead in Developing Asian Nations

North America, and Europe capture a major chunk of the market share. However, Asia Pacific has emerged as the fastest growing market, attributing to the rising incidence of hearing and vision loss, cardiovascular diseases, and kidney failure cases. Factors such as rising healthcare expenditure, surgical procedures, and improving income levels are expected to amplify the possibility of developing countries witnessing the highest growth rate during the forecast period. Growing awareness and availability of artificial organs, and medical bionics will drive the market ahead. The market will also progress rapidly here as the competition intensity is low, especially in lucrative yet untapped markets like India, and China. Innovations are underway. Moreover, growing funds toward medical research with reduced dependence on animal and human trials are eventually leading to full-scale transplantable organs. This is expected to drive Asia Pacific market to exhibit the fastest, i.e., 10.9% growth by 2027.

Key Players in Artificial Organs and Medical Bionics Market Augment R&D Investments

Key players holding a significant share in the global artificial organs and medical bionics market include Ossur hf, Medtronic plc, Cochlear Ltd, Zimmer Biomet Ltd, Second Sight Medical Products Ltd., Orthofix International N.V., DJO Global, Ekso Holdings Inc, and ReWalk Robotics. Cochlear Limited, invests more than US$ 130 million each year in R&D and participates in over 100 collaborative research programs worldwide. Developed by nib foundation partner and national charity, the Australian Institute of Neurorehabilitation (AINRehab), HELLEN recently kicked off its world-first clinical trial at the University of Newcastle. Robo Bionics launched an artificial robotic hand called Grippy- a NABL Lab Safety Tested and Certified, 3D printed Prosthetic hand with a sense of touch and multi-grip control. The altruistic innovation of this Mumbai (India)-based start-up has gained paramount recognition across the domain.

Leading Companies

• Zimmer Biomet Ltd.
• Cochlear Ltd.
• Second Sight Medical Products, Inc.
• Ossur hf
• Rewalk Robotics Ltd.
• Orthofix International N.V.
• Ekso Bionics Holdings Inc.
• Medtronic plc.

The Global Artificial Organs And Medical Bionics Market is Segmented as Below:

By Organ Type

• Kidney
• Heart
• Bones
• Ear
• Eye
• Brain
• Other

By Biomaterial

• Metals
• Polymers
• Ceramics
• Other

By Technology

• Implantable
• Wearable

By Geographic Coverage

• North America
• Europe
• Asia Pacific
• Rest of the World